Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2025-03-30 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
迈威生物2024年度募集资金存放与实际使用情况鉴证报告
Regulatory Filings
2025-03-30 Chinese
迈威生物2025年度”提质增效重回报”行动方案
Management Reports Classification · 95% confidence The document is a detailed action plan for the year 2025 by Maiwei (Shanghai) Biotechnology Co., Ltd., focusing on innovation drug R&D, commercialization, global business expansion, production capacity, corporate governance, investor communication, and management incentives. It includes extensive operational and strategic information but does not present financial statements or quarterly/yearly financial results. It is not an earnings release or annual/interim report. It is a comprehensive corporate plan and governance update, with no indication of being a regulatory filing, audit report, or legal proceeding. The document is too long and detailed to be a simple announcement or report publication notice. The content aligns best with a Management Report (MDA) category, as it explains business trends, strategy, and outlook in detail.
2025-03-30 Chinese
迈威生物关于续聘公司2025年度审计机构的公告
Audit Report / Information Classification · 90% confidence The document is an announcement regarding the reappointment of the company's audit firm for the fiscal year 2025. It details the qualifications, experience, and integrity of the audit firm, the audit fees, and the approval process by the board and supervisory committee. It does not contain any actual audit report, financial statements, or audit results. The document is relatively short (2990 characters) and serves as a formal notice about the audit firm appointment, which is to be submitted for shareholder approval. Therefore, it is an announcement related to audit services rather than the audit report itself.
2025-03-30 Chinese
海通证券股份有限公司关于迈威（上海）生物科技股份有限公司为全资子公司提供担保额度预计的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Haitong Securities regarding the estimated guarantee amount provided by the parent company to its wholly-owned subsidiaries. It includes extensive financial data of the subsidiaries, descriptions of the guarantee arrangements, board and supervisory committee approvals, and independent directors' opinions. The document references regulatory rules related to securities issuance and listing, and it is clearly a formal verification or audit opinion related to a financing guarantee matter. It is not an annual or interim financial report, nor a simple announcement. It is not a call transcript, earnings release, or M&A document. The document is a standalone audit or verification report concerning the guarantee arrangements and compliance with regulatory requirements, which fits the category of Audit Report / Information (AR). The document length (7050 characters) and content support it being a full report rather than a brief announcement or certification. Therefore, the classification is AR with high confidence.
2025-03-30 Chinese
迈威生物2024年度独立董事述职报告（赵倩）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2024 by an independent director of the company. It details the director's duties, attendance at board and committee meetings, communication with auditors, oversight of internal controls, and evaluation of company governance and compliance. It does not contain financial statements or quarterly/annual financial results but focuses on governance and director duties. This type of document is a management or director report on their activities and oversight, not a full annual report or audit report. It is not a regulatory filing or announcement but a substantive report by a board member on their annual duties. Therefore, the best fitting category is "Board/Management Information (MANG)" which covers announcements of changes or reports related to board or senior management activities, including independent director reports.
2025-03-30 Chinese
迈威生物2024年度审计报告
Annual Report Classification · 100% confidence The document contains a detailed audited financial report for the fiscal year 2024, including an audit opinion from a registered accounting firm (Ernst & Young Hua Ming), consolidated and company balance sheets, profit and loss statements, cash flow statements, notes to the financial statements, and supplementary information. The presence of an audit report section with detailed auditor responsibilities, key audit matters, and management responsibilities confirms this is a full audited financial report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, this document is classified as an Annual Report (10-K equivalent).
2025-03-30 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.